Literature DB >> 23778838

Neutrophil gelatinase-associated lipocalin and its influence on tumor progression in systemic malignancies.

Shailendra Kapoor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23778838     DOI： 10.1007/s00268-013-2131-5

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  9 in total

1.  Serum retinol binding protein-4 and neutrophil gelatinase-associated lipocalin are interrelated in pancreatic cancer patients.

Authors:  Hala O El-Mesallamy; Nadia M Hamdy; Ashraf S Zaghloul; Alaliaa M Sallam
Journal:  Scand J Clin Lab Invest       Date:  2012-10-01       Impact factor: 1.713

2.  Lipocalin 2 promotes breast cancer progression.

Authors:  Jiang Yang; Diane R Bielenberg; Scott J Rodig; Robert Doiron; Matthew C Clifton; Andrew L Kung; Roland K Strong; David Zurakowski; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer.

Authors:  Josep Martí; Josep Fuster; Anna M Solà; Georgina Hotter; Rafael Molina; Amalia Pelegrina; Joana Ferrer; Ramon Deulofeu; Constantino Fondevila; Juan Carlos García-Valdecasas
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

4.  Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Authors:  Zhimin Tong; Subhankar Chakraborty; Bokyung Sung; Pooja Koolwal; Sukhwinder Kaur; Bharat B Aggarwal; Sendurai A Mani; Robert S Bresalier; Surinder K Batra; Sushovan Guha
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

5.  Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease.

Authors:  Xeni Provatopoulou; Antonia Gounaris; Eleni Kalogera; Flora Zagouri; Ioannis Flessas; Evgenios Goussetis; Afroditi Nonni; Ioannis Papassotiriou; George Zografos
Journal:  BMC Cancer       Date:  2009-11-04       Impact factor: 4.430

6.  Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.

Authors:  Jiang Yang; Brendan McNeish; Catherine Butterfield; Marsha A Moses
Journal:  FASEB J       Date:  2012-09-14       Impact factor: 5.191

7.  Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.

Authors:  Antonia Sophie Wenners; Keyur Mehta; Sibylle Loibl; Hyerim Park; Berit Mueller; Norbert Arnold; Sigrid Hamann; Joerg Weimer; Beyhan Ataseven; Silvia Darb-Esfahani; Christian Schem; Christoph Mundhenke; Fariba Khandan; Christoph Thomssen; Walter Jonat; Hans-Juergen Holzhausen; Gunther von Minckwitz; Carsten Denkert; Maret Bauer
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

8.  The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer.

Authors:  Hyuna Sung; Ji-Yeob Choi; Sang-Ah Lee; Kyoung-Mu Lee; Sohee Han; Sujee Jeon; Minkyo Song; Yunhee Lee; Sue K Park; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Daehee Kang
Journal:  BMC Cancer       Date:  2012-05-28       Impact factor: 4.430

9.  Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.

Authors:  N Moniaux; S Chakraborty; M Yalniz; J Gonzalez; V K Shostrom; J Standop; S M Lele; M Ouellette; P M Pour; A R Sasson; R E Brand; M A Hollingsworth; M Jain; S K Batra
Journal:  Br J Cancer       Date:  2008-04-08       Impact factor: 7.640
  9 in total
  1 in total

1.  The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.

Authors:  Linghong Guo; Honghong Ren; Lutong Pu; Xingyu Zhu; Yin Liu; Xuelei Ma
Journal:  Cancer Manag Res       Date:  2020-08-13       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.